- Business24 February 2023
Adalvo is pleased to announce the successful EU dossier submission for Dalbavancin powder. This achievement further strengthens our infectiology product pipeline and positions Adalvo amongst the few players able to...
- Business22 February 2023
We are pleased to announce our successful Pivotal BE results for Mirabegron prolonged release tablets. We will proceed with DCP submission, which is scheduled for June 2023
- Business21 February 2023
Adalvo is pleased to announce that we have entered into a partnership with ADVANZ PHARMA, signing an exclusive licensing and supply agreement for a complex, specialty injectable generic for multiple...
- Business03 February 2023
We are pleased to announce that we have now completed our Pivotal BE program for Dapagliflozin 10mg film-coated tablets.
- Business01 February 2023
Adalvo partners with Eurofarma & Lotus, bringing high-performance medications to Brazil, indicated in the treatment of multiple myeloma
Nuvyor (lenalidomide) is the first similar announced in the Brazilian market and marks the strengthening of pharmaceuticals in the area of oncologic hematology. Adalvo is pleased to announce that...
- Business27 January 2023
Adalvo is delighted to announce the successful DCP approval for Lisdexamfetamine hard capsules, which has been developed in close collaboration with one of our strategic partners.
- Business24 January 2023
Adalvo is delighted to announce the completion of second wave MA approvals for Solifenacin + Tamsulosin, in various EU markets, with several successful DCP approvals.
- Business20 January 2023
Adalvo extends its strategic collaboration with Bioventure, the subsidiary of Healthcare Division of Yas Holding, within the MENA region.
Adalvo is pleased to announce that we have extended our strategic partnership with Bioventure, the subsidiary of Healthcare Division of Yas Holding, signing a licensing deal for four molecules, within...
- Business18 January 2023
Adalvo is pleased to announce the successful EU dossier submission for Apremilast Film-Coated tablets on day-1, after expiry of data exclusivity.
- Business11 January 2023
Strategic partnership in Europe extended to cover five additional molecules in therapeutic categories including oncology and diabetes
- Business09 January 2023
Zentiva extends its collaboration with Adalvo and strengthens its offering in Respiratory, CNS and Dermatology
Adalvo is pleased to announce that we have extended our strategic partnership with Zentiva, signing a licensing deal for three molecules, within Europe.
- Business27 December 2022
Adalvo and Frontier Biopharma/Zdravlje Sign Licensing & Supply Agreement for Central & Eastern Europe
Adalvo and Frontier Biopharma/Zdravlje (“Frontier”) are pleased to announce their collaboration in several therapeutic areas for the markets of Central and Eastern Europe and the Balkans. Over the next months...
- Business21 December 2022
Adalvo announces successful DCP closure for Desmopressin 60mcg, 120mcg and 240mcg sub-lingual tablets
Adalvo is delighted to announce the successful DCP closure for Desmopressin 60mcg, 120mcg and 240mcg sub-lingual tablets. With this achievement, we believe we will be amongst the first companies to...
- Business12 December 2022
Adalvo is pleased to announce the addition of Ibrutinib 140mg, 280mg, 420mg & 560mg Film Coated Tablets to our product Portfolio.
- Business09 December 2022
Adalvo is delighted to announce the successful Pivotal BE study of our Dydrogesterone 10mg tablets. Our dossier is ready for immediate submission and we expect Adalvo to be amongst the first...
- Business07 December 2022
Adalvo is delighted to announce the successful DCP submission for Nintedanib 100mg & 150mg soft gel capsules. Our product is being developed in collaboration with our sister Company, which forms...
- Business05 December 2022
Adalvo is pleased to announce that we have partnered with MS Pharma, signing a licensing deal for Solifenacin + Tamsulosin in the MENA region.
- Business02 December 2022
Adalvo is pleased to announce the addition of Riociguat 0.5mg, 1mg, 1.5mg, 2mg & 2.5mg Film Coated Tabletsto our product Portfolio.
- Business29 November 2022
Adalvo is pleased to announce the successful launch of Enzalutamide Soft Gel Capsule in LATAM, fulfilling our commitment to our partners, and strengthening our presence in select LATAM countries.